Applying the CHA2DS2-VASc score to predict the risk of future acute coronary syndrome in patients receiving catheter ablation for atrial fibrillation

Ching Yao Chou, Yun Yu Chen, Yenn Jiang Lin*, Kuo Liong Chien, Shih Lin Chang, Ta Chuan Tuan, Li Wei Lo, Tze Fan Chao, Yu Feng Hu, Fa Po Chung, Jo Nan Liao, Chin Yu Lin, Ting Yung Chang, Shih Ann Chen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Objective: It remains unknown whether catheter ablation for atrial fibrillation (AF) reduces future acute coronary syndrome (ACS) risk or whether the CHA2DS2-VASc score has a role in predicting this risk. We aimed to compare very long-term risk of ACS between patients who received catheter ablation to AF or antiarrhythmic medications and controls without AF. Methods: Propensity scores were calculated for each patient and used to assemble a cohort of 787 patients undergoing AF ablation in 2003–2012. Patients were compared to an equal number of AF patients treated with antiarrhythmic medications and a control group without AF. Patients with previous coronary events were excluded. The primary endpoint was ACS occurrence. Results: Baseline clinical characteristics were comparable. After a mean 9.1 ± 3.2-year follow-up, the ablation group had lower incidence of new onset ACS than the medication and non-AF control groups (annual incidence: 0.15%. 0.78%, and 0.35%; with 2.67, 4.16, and 10.44 cases/1000 person-years, respectively; P < 0.001). After adjusting for multiple confounders, the ablation group had lower future ACS risk than the medication (hazard ratio [HR]: 0.20, 95% confidence interval [CI]: 0.13–0.30) and control groups (HR: 0.30, 95% CI: 0.20–0.45). The CHA2DS2-VASc score was a strong predictor of ACS (HR: 1.61, 95% CI: 1.47–1.76; AUC: 85.9%, 95% CI: 78.5–93.2%). A baseline CHA2DS2-VASc score ≥ 4 predicted future ACS (positive predictive rate: 14.3%). Conclusions: This study suggested that catheter ablation for AF may be beneficial to reduce future ACS risk in AF patients, and a high baseline CHA2DS2-VASc score can predict future acute coronary events.

Original languageEnglish
Article number100567
JournalIJC Heart and Vasculature
Volume29
DOIs
StatePublished - Aug 2020

Keywords

  • Acute coronary syndrome
  • Atrial fibrillation
  • CHADS-VASc score

Fingerprint

Dive into the research topics of 'Applying the CHA2DS2-VASc score to predict the risk of future acute coronary syndrome in patients receiving catheter ablation for atrial fibrillation'. Together they form a unique fingerprint.

Cite this